NCT02224235 - COBRA SHIELD OCT Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Stable Angina

Interventions

DRUG

Aspirin

75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)

DEVICE

Resolute Integrity DES

DEVICE

COBRA PzF

DRUG

DAPT

At the discretion of the investigator as to which DAPT is administered (per local practice)

Trial Locations (2)

Heart Center, Turku University Hospital, Turku

Satakunta Central Hospital, Pori